NASDAQ$SKIN
SkinHealth Systems Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
BeautyHealth reported double-digit net sales growth driven by demand for Hydrafacial and reaffirmed its 2023 net sales and 2025 financial guidance, while refining 2023 adjusted EBITDA margin guidance.
BeautyHealth reported a 13% year-over-year increase in net sales, reaching $117.5 million. Net income was $3.4 million, and the adjusted EBITDA margin was 15.1%. The company reaffirmed its 2023 net sales and long-term 2025 financial guidance, and refined its 2023 adjusted EBITDA margin to a more precise 18%-19% range.
- Net sales increased by 13% year-over-year to $117.5 million.
- Consumables net sales grew by 34% year-over-year.
- Net income was $3.4 million.
- Adjusted EBITDA margin was 15.1%.
Headline financials
Revenue & EPS history
Beauty Health · Revenue · Quarterly
$117M
Revenue by segment
Beauty Health · $118M total across 2 segments · Q2 2023
- Delivery Systems$65.6M+1.2%55.8%
- Consumables$51.9M+33.8%44.2%
Forward guidance
The Company re-affirmed its fiscal year 2023 net sales due to continued demand for Hydrafacial, strong trends in China and ability to drive operating leverage, and refined its fiscal year 2023 adjusted EBITDA guidance to a range of 18-19% from 18-20% previously. The Company retracted its 2023 fiscal year 2023 adjusted gross margin guidance due to Q2 margin headwinds carrying into the back half of 2023. The Company re-affirmed its fiscal year 2025 long-range outlook, due to continued strong business fundamentals, fortified leadership team and its expected pipeline of innovation.
Tailwinds
- Continued demand for Hydrafacial.
- Strong trends in China.
- Ability to drive operating leverage.
- Continued strong business fundamentals.
- Fortified leadership team and its expected pipeline of innovation.
Headwinds
- No material deterioration in general market conditions or other unforeseen circumstances beyond the Company's control.
- Excludes any unannounced acquisitions, dispositions or financings during 2023.
- Assumes a largely re-opened global market, which would be negatively impacted if closures related to COVID-19 or other restrictive measures are reimplemented.
- Assumes no material deterioration in foreign currency exchange rates.
- Q2 margin headwinds carrying into the back half of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+0.6%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-1.9%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+52.1%
Q1 2025
Best reaction
-61.4%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.5% | -29.9% | -34.9% | |
| Q4 2025 | +19.8% | +11.3% | -15.3% | |
| Q3 2025 | +8.7% | +3.1% | +13.2% | |
| Q1 2025 | +52.1% | +19.4% | +29.0% | |
| Q4 2024 | -5.6% | -9.9% | -26.1% | |
| Q3 2024 | +5.1% | -13.1% | -14.2% | |
| Q2 2024 | -10.4% | +0.8% | +12.8% | |
| Q1 2024 | -20.1% | -18.4% | -39.9% | |
| Q4 2023 | +16.8% | -0.8% | +4.4% | |
| Q3 2023 | -61.4% | -37.2% | -14.7% | |
| Q2 2023 | -6.0% | -12.9% | -24.2% | |
| Q1 2023 | -2.8% | -0.2% | -20.8% | |
| Q4 2022 | +8.7% | +13.5% | +7.4% | |
| Q3 2022 | -25.3% | -12.3% | -4.1% | |
| Q2 2022 | -8.3% | -8.8% | -18.5% | |
| Q1 2022 | -5.4% | +6.6% | +8.9% | |
| Q4 2019 | +4.0% | -4.1% | -12.9% | |
| Q4 2021 | +23.4% | +43.1% | +27.6% | |
| Q3 2021 | -11.9% | -8.0% | -13.9% | |
| Q2 2020 | +8.2% | +7.4% | +26.8% | |
| Q2 2021 | +10.6% | +23.9% | +30.3% | |
| Q1 2021 | +12.8% | +15.9% | +44.7% | |
| Q4 2020 | +2.8% | -0.9% | -10.0% | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro